Editas Medicine made significant progress in advancing reni-cel, despite a 65% drop in stock price. Click here to read why ...
Can the BLA, a secular nationalist militant group seeking complete separation from Pakistan, genuinely form an alliance with ...
Brazilian Legal Amazonia (BLA)—which comprises the entirety of the Amazon Basin located in Brazil and vast adjacent swathes ...
Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced it has completed a successful pre-Biologics ...
SAN DIEGO - 专注于细胞和外泌体疗法治疗罕见疾病的生物技术公司Capricor Therapeutics (NASDAQ: CAPR)宣布计划向美国食品和药物管理局(FDA)提交其主要产品候选药物deramiocel的生物制品许可申请(BLA),用于治疗杜氏肌营养不良症(DMD)患者的心肌病。该公司预计将于2024年10月开始滚动提交流程,并在年底前完成。 这一决定是在最近与FDA讨论后 ...
Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...
AstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan ...